Health Benefits of Mushrooms

A research-backed overview of the potential health benefits of medicinal, gourmet, and psychoactive mushroom species. From immune support to mental health.

Medicinal Mushrooms

Medicinal mushrooms have been used in traditional medicine for thousands of years, particularly in Chinese, Japanese, and Korean medicine. Modern research is now providing scientific evidence for many of these traditional uses.

Lion's Mane (Hericium erinaceus)

Lion's Mane is one of the most extensively researched medicinal mushrooms, particularly for its effects on the nervous system. It is unique among mushrooms for its ability to stimulate the production of Nerve Growth Factor (NGF) and Brain-Derived Neurotrophic Factor (BDNF) — proteins essential for the growth, maintenance, and survival of neurons.

Key research areas

Turkey Tail (Trametes versicolor)

Turkey Tail is arguably the most clinically studied medicinal mushroom in the world, particularly in the context of cancer research. It contains two extensively researched polysaccharides: PSK (Polysaccharide-K / Krestin) and PSP (Polysaccharopeptide).

Key research areas

Reishi (Ganoderma lucidum)

Known as the "Mushroom of Immortality" in traditional Chinese medicine, Reishi has been used for over 2,000 years. It is classified as an adaptogen — a substance that helps the body resist physical, chemical, and biological stressors.

Key research areas

Cordyceps (Cordyceps militaris)

Cordyceps gained worldwide attention after Chinese Olympic athletes attributed their record-breaking performances to Cordyceps supplementation in the 1993 National Games. While the original wild Cordyceps (C. sinensis) parasitises caterpillars and costs thousands per kilogram, the cultivated species C. militaris produces the same key compound — cordycepin — and can be grown on rice substrate at home.

Key research areas

Gourmet Mushrooms with Health Benefits

Even common culinary mushrooms offer significant nutritional and health benefits beyond their macronutrient content.

Oyster Mushrooms (Pleurotus species)

Oyster mushrooms — including Pink, Blue, and King Oyster — are among the easiest mushrooms to grow and some of the most nutritious.

• Cholesterol reduction — contain lovastatin, a naturally occurring statin compound. Studies show regular consumption can reduce LDL cholesterol by up to 30% in some individuals.
• Antioxidants — rich in ergothioneine, a powerful antioxidant that protects cells from oxidative damage. Ergothioneine is not produced by the human body and must come from diet — mushrooms are the richest known source.
• Immune support — beta-glucans in oyster mushrooms stimulate immune cell activity, similar to (though less potent than) medicinal species.
• Vitamin D — when exposed to sunlight or UV light, oyster mushrooms produce significant amounts of vitamin D2. A few hours of sun exposure can increase vitamin D content to levels equivalent to a supplement.
• Protein — up to 30% protein by dry weight, with a complete amino acid profile. King Oyster in particular has a meaty texture that makes it an excellent plant-based protein source.

Shiitake (Lentinula edodes)

Shiitake is the second most cultivated mushroom in the world and has been used in Asian medicine for centuries.

• Lentinan — a beta-glucan polysaccharide approved as an adjunct cancer treatment in Japan. Stimulates immune cell production and activity.
• Cardiovascular health — contains eritadenine, which lowers cholesterol by accelerating its removal from the bloodstream. Also contains compounds that reduce blood pressure.
• Antimicrobial — shiitake extracts show activity against bacteria, viruses, and fungi. Lentinan has demonstrated antiviral properties against influenza and HIV in laboratory studies.
• B vitamins — excellent source of B2 (riboflavin), B3 (niacin), B5 (pantothenic acid), and B6. Important for energy metabolism and nervous system function.
• Vitamin D — like oyster mushrooms, shiitake produces vitamin D when exposed to UV light. Sun-dried shiitake can contain over 1,000 IU of vitamin D per serving.

Psychoactive Mushrooms — Psilocybin Research

Psilocybin — the active compound in psychoactive mushrooms — is the subject of a rapidly growing body of clinical research. Major institutions including Johns Hopkins University, Imperial College London, and NYU have published groundbreaking studies on its therapeutic potential.

For practical harm-reduction information — dose ranges, drug interactions (particularly antidepressants and lithium), set & setting, and what to do if a trip becomes difficult — see the Dosage & Safety guide.

Depression

Psilocybin-assisted therapy has shown remarkable results in treating treatment-resistant depression — depression that has not responded to conventional antidepressants.

• Johns Hopkins (2020) — a randomised controlled trial found that two sessions of psilocybin therapy produced rapid, large, and sustained antidepressant effects. 71% of participants showed a greater than 50% reduction in depression severity at 4 weeks. 54% were in remission.
• Imperial College London (2021) — compared psilocybin to escitalopram (a leading SSRI). Psilocybin was at least as effective as the SSRI over 6 weeks, with faster onset and fewer side effects.
• Mechanism — psilocybin appears to work by increasing neuroplasticity (the brain's ability to form new connections) and reducing activity in the Default Mode Network (DMN), which is overactive in depression. Unlike SSRIs, which blunt emotions, psilocybin therapy appears to help patients process and integrate difficult emotions.

Anxiety & End-of-Life Distress

• NYU & Johns Hopkins (2016) — two landmark studies showed that a single dose of psilocybin, combined with psychotherapy, produced immediate and sustained reductions in anxiety and depression in patients with life-threatening cancer diagnoses. Effects lasted 6+ months in the majority of participants.
• 80% of participants showed clinically significant decreases in distress, with many describing the experience as one of the most meaningful of their lives.
• Existential distress — psilocybin therapy appears uniquely effective at addressing the existential anxiety and demoralisation that often accompanies terminal illness, an area where conventional treatments have limited efficacy.

Addiction

• Smoking cessation (Johns Hopkins, 2014) — an open-label pilot study found that psilocybin-assisted therapy helped 80% of long-term smokers quit, with 67% remaining abstinent at 12 months. This compares to roughly 30% for the best conventional treatments.
• Alcohol dependence (NYU, 2022) — a randomised controlled trial showed that psilocybin therapy significantly reduced heavy drinking days by 83% compared to 51% in the control group.
• Mechanism — psilocybin may help break addictive patterns by disrupting habitual neural pathways and providing a "reset" that allows patients to gain perspective on their behaviour.

PTSD

• Early-stage clinical trials are investigating psilocybin for PTSD treatment. Preliminary results are promising, with significant reductions in PTSD symptoms reported.
• The mechanism is thought to involve reduced fear response in the amygdala and enhanced emotional processing, similar to the effects seen in depression studies.
• Several Phase 2 trials are currently underway at major research institutions.

Neuroplasticity & Brain Connectivity

• Increased neural connectivity — brain imaging studies show that psilocybin dramatically increases connections between brain regions that don't normally communicate. This "hyperconnectivity" is thought to underlie the therapeutic effects.
• Neurogenesis — animal studies show psilocybin promotes the growth of new neurons and new dendritic connections, particularly in the hippocampus (memory and learning centre).
• Default Mode Network — psilocybin reduces activity in the DMN, a network associated with ego, rumination, and self-referential thinking. Overactivity in this network is linked to depression, anxiety, and addiction.

Microdosing

Microdosing involves taking very small, sub-perceptual doses of psilocybin (typically 1/10th to 1/20th of a full dose) on a regular schedule. While large-scale clinical trials are limited, survey data and small studies report:

• Enhanced creativity and divergent thinking
• Improved mood and emotional resilience
• Increased focus and flow states
• Reduced anxiety without the perceptual effects of a full dose
• Common protocols — Fadiman protocol (1 day on, 2 days off) and Stamets protocol (4 days on, 3 days off)

It is important to note that microdosing research is still in early stages, and some studies suggest that placebo effects may account for a significant portion of reported benefits. More rigorous controlled trials are needed.

General Mushroom Nutrition

All edible mushrooms — regardless of species — share a nutritional profile that makes them one of the most nutrient-dense foods available.

Quick Reference — Health Benefits by Species

Further Reading

For those interested in the primary research, here are some key published studies:

• Davis AK et al. (2021) — "Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder" — JAMA Psychiatry
• Carhart-Harris R et al. (2021) — "Trial of Psilocybin versus Escitalopram for Depression" — New England Journal of Medicine
• Griffiths RR et al. (2016) — "Psilocybin produces substantial and sustained decreases in depression and anxiety" — Journal of Psychopharmacology
• Johnson MW et al. (2014) — "Pilot study of psilocybin for tobacco addiction" — Journal of Psychopharmacology
• Bogucka-Kocka A et al. (2020) — "Medicinal Mushrooms — A Review" — Molecules
• Friedman M (2015) — "Chemistry, Nutrition, and Health-Promoting Properties of Hericium erinaceus Mushroom" — Journal of Agricultural and Food Chemistry